Advertisement

Diabetologia

, Volume 61, Issue 10, pp 2189–2201 | Cite as

Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome

  • Manabu Kondo
  • Katsuya Tanabe
  • Kikuko Amo-Shiinoki
  • Masayuki Hatanaka
  • Tsukasa Morii
  • Harumi Takahashi
  • Susumu Seino
  • Yuichiro Yamada
  • Yukio Tanizawa
Article

Abstract

Aims/hypothesis

Loss of functional beta cells results in a gradual progression of insulin insufficiency in Wolfram syndrome caused by recessive WFS1 mutations. However, beta cell dysfunction in Wolfram syndrome has yet to be fully characterised, and there are also no specific treatment recommendations. In this study, we aimed to characterise beta cell secretory defects and to examine the potential effects of a glucagon-like peptide-1 (GLP-1) receptor agonist on diabetes in Wolfram syndrome.

Methods

Insulin secretory function was assessed by the pancreatic perfusion method in mice used as a model of Wolfram syndrome. In addition, granule dynamics in living beta cells were examined using total internal reflection fluorescence microscopy. Acute and chronic effects of exendin-4 (Ex-4) on glucose tolerance and insulin secretion were examined in young Wfs1−/− mice without hyperglycaemia. Molecular events associated with Ex-4 treatment were investigated using pancreatic sections and isolated islets. In addition, we retrospectively observed a woman with Wolfram syndrome who had been treated with liraglutide for 24 weeks.

Results

Treatment with liraglutide ameliorated our patient’s glycaemic control and resulted in a 20% reduction of daily insulin dose along with an off-drug elevation of fasting C-peptide immunoreactivity. Glucose-stimulated first-phase insulin secretion and potassium-stimulated insulin secretion decreased by 53% and 59%, respectively, in perfused pancreases of 10-week-old Wfs1−/− mice compared with wild-type (WT) mice. The number of insulin granule fusion events in the first phase decreased by 41% in Wfs1−/− beta cells compared with WT beta cells. Perfusion with Ex-4 increased insulin release in the first and second phases by 3.9-fold and 5.6-fold, respectively, in Wfs1−/− mice compared with perfusion with saline as a control. The physiological relevance of the effects of Ex-4 was shown by the fact that a single administration potentiated glucose-stimulated insulin secretion and improved glucose tolerance in Wfs1−/− mice. Four weeks of administration of Ex-4 resulted in an off-drug amelioration of glucose excursions after glucose loading in Wfs1−/− mice, with insulin secretory dynamics that were indistinguishable from those in WT mice, despite the fact that there was no alteration in beta cell mass. In association with the functional improvements, Ex-4 treatment reversed the increases in phosphorylated eukaryotic initiation factor (EIF2α) and thioredoxin interacting protein (TXNIP), and the decrease in phosphorylated AMP-activated kinase (AMPK), in the beta cells of the Wfs1−/− mice. Furthermore, Ex-4 treatment modulated the transcription of oxidative and endoplasmic reticulum stress-related markers in isolated islets, implying that it was able to mitigate the cellular stresses resulting from Wfs1 deficiency.

Conclusions/interpretation

Our study provides deeper insights into the pathophysiology of beta cell dysfunction caused by WFS1 deficiency and implies that activation of the GLP-1 receptor signal may alleviate insulin insufficiency and aid glycaemic control in Wolfram syndrome.

Keywords

Diabetes mellitus Endoplasmic reticulum stress Glucagon-like peptide-1 Insulin secretion Pancreatic beta cell Wolfram syndrome 

Abbreviations

AMPK

AMP-activated kinase

ATP6V1a

Vacuolar-type H+-ATPase V1A

BafA1

Bafilomycin A1

CPI

CPR index

CPR

C-peptide immunoreactivity

EIF2α

Eukaryotic initiation factor 2α

ER

Endoplasmic reticulum

EX-4

Exendin-4

GLP-1

Glucagon-like peptide-1

GSIS

Glucose-stimulated insulin secretion

KRBH

KRB HEPES

SUIT

Secretory units of islets in transplantation

TIRFM

Total internal reflection fluorescence microscopy

TXNIP

Thioredoxin interacting protein

WT

Wild-type

WFS1

Wolfram syndrome 1 protein

Notes

Acknowledgements

The authors would like to thank members of the division of Yamaguchi University Graduate School of Medicine for their helpful discussion with preparing the manuscript.

Contribution statement

All authors participated substantially in the investigations reported here as indicated. KT and YT conceived and designed experimental studies, collected, analysed and interpreted data, and drafted and critically revised the manuscript. MK designed the study, conducted experiments, collected, analysed and interpreted data and wrote and revised the manuscript. KA-S, MH, TM, and HT designed experimental studies and collected, analysed and interpreted data; they also critically reviewed the manuscript and gave valuable suggestions for its revision. SS and YY assisted in the design of the study and contributed significantly to data interpretation, critical reading and revision of the manuscript. All authors carefully read and approved the final version to be published. YT is the guarantor of this work.

Funding

KT is supported by a Grant-in-Aid for Scientific Research (grant number 16K09752). YT is supported by a Grant-in-Aid for Scientific Research (grant numbers 23390080 and 15H04849) and by Takeda Science Foundation. KA-S is supported by a Grant-in-Aid for Scientific Research (grant number 15K21198), a Japan Diabetes Society Junior Scientist Development Grant supported by Novo Nordisk Pharma Ltd., a Grant for Front Runner of Future Diabetes Research, and Grants for young researchers from the Japan Association for Diabetes Education and Care and from Banyu Life Science Foundation International. MH is supported by a Grant-in-Aid for Scientific Research (grant number 15K09390).

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Supplementary material

125_2018_4679_MOESM1_ESM.pdf (1.7 mb)
ESM (PDF 1.67 mb)

References

  1. 1.
    Barrett TG, Bundey SE, Macleod AF (1995) Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346:1458–1463CrossRefPubMedGoogle Scholar
  2. 2.
    Minton JA, Rainbow LA, Ricketts C, Barrett TG (2003) Wolfram syndrome. Rev Endocr Metab Disord 4:53–59CrossRefPubMedGoogle Scholar
  3. 3.
    Marshall BA, Permutt MA, Paciorkowski AR et al (2013) Phenotypic characteristics of early Wolfram syndrome. Orphanet J Rare Dis 8:64CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Matsunaga K, Tanabe K, Inoue H et al (2014) Wolfram syndrome in the Japanese population; molecular analysis of WFS1 gene and characterization of clinical features. PLoS One 9:e106906CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Karasik A, O'Hara C, Srikanta S et al (1989) Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram’s syndrome. Diabetes Care 12:135–138CrossRefPubMedGoogle Scholar
  6. 6.
    Hardy C, Khanim F, Torres R et al (1999) Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1. Am J Hum Genet 65:1279–1290CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hofmann S, Philbrook C, Gerbitz KD, Bauer MF (2003) Wolfram syndrome: structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. Hum Mol Genet 12:2003–2012CrossRefPubMedGoogle Scholar
  8. 8.
    Inoue H, Tanizawa Y, Wasson J et al (1998) A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 20:143–148CrossRefPubMedGoogle Scholar
  9. 9.
    Takeda K, Inoue H, Tanizawa Y et al (2001) WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 10:477–484CrossRefPubMedGoogle Scholar
  10. 10.
    Hatanaka M, Tanabe K, Yanai A et al (2011) Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 20:1274–1284CrossRefPubMedGoogle Scholar
  11. 11.
    Cagalinec M, Liiv M, Hodurova Z et al (2016) Role of mitochondrial dynamics in neuronal development: mechanism for Wolfram syndrome. PLoS Biol 14:e1002511CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ishihara H, Takeda S, Tamura A et al (2004) Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 13:1159–1170CrossRefPubMedGoogle Scholar
  13. 13.
    Takei D, Ishihara H, Yamaguchi S, Yamada et al (2006) WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum. FEBS Lett 580:5635–5640CrossRefPubMedGoogle Scholar
  14. 14.
    Fonseca SG, Ishigaki S, Oslowski CM et al (2010) Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 120:744–755CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Deriy LV, Gomez EA, Jacobson DA et al (2009) The granular chloride channel ClC-3 is permissive for insulin secretion. Cell Metab 10:316–323CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Orci L, Halban P, Perrelet A, Amherdt M, Ravazzola M, Anderson RG (1994) pH-independent and -dependent cleavage of proinsulin in the same secretory vesicle. J Cell Biol 126:1149–1156CrossRefPubMedGoogle Scholar
  17. 17.
    Fonseca SG, Fukuma M, Lipson KL et al (2005) WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 280:39609–39615CrossRefPubMedGoogle Scholar
  18. 18.
    Lu S, Kanekura K, Hara T et al (2014) A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proc Natl Acad Sci U S A 111:E5292–E5301CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yamada Y, Fukuda K, Fujimoto S et al (2006) SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 74:222–226CrossRefPubMedGoogle Scholar
  20. 20.
    Miki T, Minami K, Shinozaki H et al (2005) Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 54:1056–1063CrossRefPubMedGoogle Scholar
  21. 21.
    Shibasaki T, Takahashi H, Miki T et al (2007) Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 104:19333–19338CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tanabe K, Liu Z, Patel S et al (2008) Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol 6:e37CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Girish V, Vijayalakshmi A (2004) Affordable image analysis using NIH Image/ImageJ. Indian J Cancer 41:47PubMedGoogle Scholar
  24. 24.
    Gharanei S, Zatyka M, Astuti D et al (2013) Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Hum Mol Genet 22:203–217CrossRefPubMedGoogle Scholar
  25. 25.
    Volchuk A, Ron D (2010) The endoplasmic reticulum stress response in the pancreatic beta-cell. Diabetes Obes Metab 12(Suppl 2):48–57.zCrossRefPubMedGoogle Scholar
  26. 26.
    Matsuda T, Takahashi H, Mieda Y et al (2015) Regulation of pancreatic beta cell mass by cross-interaction between CCAAT enhancer binding protein beta induced by endoplasmic reticulum stress and AMP-activated protein kinase activity. PLoS One 10:e0130757CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Nyblom HK, Sargsyan E, Bergsten P (2008) AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels. J Mol Endocrinol 41:187–194CrossRefPubMedGoogle Scholar
  28. 28.
    Steinberg GR, Kemp BE (2009) AMPK in health and disease. Physiol Rev 89:1025–1078CrossRefPubMedGoogle Scholar
  29. 29.
    Shaked M, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G (2011) AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cells. PLoS One 6:e28804CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wu N, Zheng B, Shaywitz A et al (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49:1167–1175CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Shalev A (2014) Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic beta-cell. Mol Endocrinol 28:1211–1220CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Saxena G, Chen J, Shalev A (2010) Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem 285:3997–4005CrossRefPubMedGoogle Scholar
  33. 33.
    Li DQ, Jing X, Salehi A et al (2009) Suppression of sulfonylurea- and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3. Cell Metab 10:309–315CrossRefPubMedGoogle Scholar
  34. 34.
    Verhage M, Sorensen JB (2008) Vesicle docking in regulated exocytosis. Traffic 9:1414–1424CrossRefPubMedGoogle Scholar
  35. 35.
    Yusta B, Baggio LL, Estall JL et al (2006) GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391–406CrossRefPubMedGoogle Scholar
  36. 36.
    Dor Y, Glaser B (2013) beta-cell dedifferentiation and type 2 diabetes. N Engl J Med 368:572–573CrossRefPubMedGoogle Scholar
  37. 37.
    Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ (2017) Glucagon-like peptide-1 and the central/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab 28:88–103CrossRefPubMedGoogle Scholar
  38. 38.
    Urano F (2016) Wolfram Syndrome: diagnosis, management, and treatment. Curr Diab Rep 16:6CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Manabu Kondo
    • 1
  • Katsuya Tanabe
    • 1
  • Kikuko Amo-Shiinoki
    • 1
  • Masayuki Hatanaka
    • 1
  • Tsukasa Morii
    • 2
  • Harumi Takahashi
    • 3
  • Susumu Seino
    • 3
  • Yuichiro Yamada
    • 2
  • Yukio Tanizawa
    • 1
  1. 1.Division of Endocrinology, Metabolism, Hematological Sciences and TherapeuticsYamaguchi University Graduate School of MedicineUbeJapan
  2. 2.Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
  3. 3.Division of Molecular and Metabolic Medicine, Department of Physiology and Cell BiologyKobe University Graduate School of MedicineKobeJapan

Personalised recommendations